Indeed, a larger cohort or epidemiologic studies are needed to scrutinize whether treatment of skin cancer with α-MSH or other more stable agonists of MC-1R might potentially lead to an improvement of anti-tumoral immune responses. Here, MC1R is linked to skin cancer.